Clinical efficacy of secukinumab in treating sleep disorders in psoriatic patients
ZHOU Cuimei
LIU Min
LIU Chang
REN Yuqian
MENG Jichao
YU Yaxin
LIN Xiaoru
Abstract：Objective To evaluate the efficacy and safety of secukinumab in treating psoriatic patients with sleep disorders,and its impact on sleep quality.Methods A total of 144 patients diagnosed with psoriasis complicated by sleep disorders at Jinzhou Central Hospital from October 2022 to October 2024 were enrolled and randomly divided into the experimental group and control group,with 72 cases each.The experimental group was treated with secukinumab,while the con-trol group received conventional therapies(Xiaoyin Granules,acitretin,Bixie Xiatare Tablets,calcipotriol ointment,compound glycyrrhizin tablets,and halometasone ointment)for 3 months.The PASI,BSA,DLQI,PSQI,and ISI scores in both groups were recorded at baseline and after 4-,8-,and 12-week treatment.The PASI improvement rate and its correlation with PSQI scores were calculated.Adverse reactions were observed,and patients were followed up to observe recur-rence.Results After 4-,8-,and 12-week treatment,the BSA,PASI,DLQI,PSQI,and ISI scores in the experimental group were significantly decreased from baseline levels(all P＜0.05),and significantly lower than that in the control group(all P＜0.05).PASI improvement rate in the experimental group was significantly higher than that in the control group(all P＜0.05).Spearman correlation analysis showed a negative correlation between PSQI scores and PASI im-provement rate.The incidence of adverse reactions in the experimental group was significantly low-er than that in the control group(5.56％vs.18.06％,x2=5.40,P=0.02).During a 3-month follow-up period,the recurrence rate in the experimental group was significantly lower than that in the control group(1.39％ vs.19.44％,x2=12.58,P＜0.05).Conclusions Secukinumab improves skin lesion in psoriatic patients with sleep disorders,effectively reduces skin inflamma-tion,and enhances both quality of life and sleep.It demonstrates high safety,with low rates of ad-verse reactions and recurrence.As skin lesions improve,patients' sleep quality gradually increases.
Keywords：psoriasissecukinumabconventional treatmentsleep disordersbiologics
Publication Date：2025-07-28
Online Publishing Date：2025-08-20(First online date of this platform, not the publication date of the document)
Pages：6( 524-529 )